Progress in research of clinical trials of herpes zoster vaccines
10.16462/j.cnki.zhjbkz.2019.11.022
- Author:
Juan LI
1
;
Jing-xin LI
;
Peng-fei JIN
;
Hong-xiu ZHANG
;
Feng-cai ZHU
Author Information
1. School of Public Health, Nanjing Medical University, Nanjing 211166, China
- Publication Type:Research Article
- Keywords:
Herpes zoster;
Vaccine;
Clinical trial;
Protective efficacy;
Safety
- From:
Chinese Journal of Disease Control & Prevention
2019;23(11):1409-1414
- CountryChina
- Language:Chinese
-
Abstract:
Herpes zoster (HZ) is more common in middle-aged and elderly people, and is caused by varicella-zoster virus (VZV) that is latent in sensory ganglia. In recent years, due to various reasons, especially the aging of China's population has become more serious, the incidence of HZ in China has risen sharply. Although HZ is self-limited, its complications will still reduce the quality of life of patients and increase the economic burden of patients' families and society. In order to reduce the incidence and improve the quality of life of the elderly in their later years, the development of safe and effective HZ vaccine may be an important and effective measure. This article aims to make a brief review of the progress in research for clinical trials of HZ vaccines, so as to provide a reference for the use of HZ vaccine and the prevention and control of HZ disease in China.
